Tag: neuroendocrine tumors

14 Inspirational Carcinoid and Neuroendocrine Tumor Survivor Stories

Living with a rare disease is especially challenging on many levels.  Carcinoid cancer and neuroendocrine tumor patients are acutely aware of these challenges – including getting a proper diagnosis and finding a physician who specializes in treating…

California Carcinoid and Neuroendocrine Tumor Conference Scheduled for January

Carcinoid and neuroendocrine tumor patients and their families are invited to attend the 2012 NET Patient Half Day Conference on Sunday, January 22 in San Francisco, California.  The latest developments in NET cancers, including clinical trials, …

Worldwide NET Cancer Awareness Day Update: Events from Australia to Europe to North America

Go around the globe for the second Worldwide NET Cancer Awareness Day (WNCAD) on November 10, 2011. Throughout that day, videos featuring NET events and experts will air on www.netcancerday.org  as the sun travels west, from Australia to Europe to North…

New Feature for Medical Professionals on Carcinoid Cancer Foundation Website

The Carcinoid Cancer Foundation is pleased to announce that a new feature for the medical community has been added to its website, www.carcinoid.org.  The section is entitled Continuing Medical Education (CME).   Upcoming events include:

• The Penn

Pancreatic Neuroendocrine Tumors: A Rare Cancer

From your next door neighbor to Steve Jobs, co-founder of Apple who just announced that he is stepping down as CEO of the company, pancreatic neuroendocrine tumors (pNETs) affect less than 1 person in 100,000 in the United States.  This rare cancer is often…

Breaking News: Pancreatic NET Cancer Patient Steve Jobs Steps Down as CEO of Apple

On August 24, 2011, Steve Jobs, CEO of Apple, announced that he was stepping down from his position.  In his letter to the Apple Board of Directors and the Apple Community, Mr. Jobs wrote, “I have always said if there ever came a day when I could no longer meet…

Phase II Clinical Trial Recruiting Carcinoid and Related Neuroendocrine Tumor Patients

Participants are being recruited for a Phase II clinical study of capecitabine and temozolomide (CAPTEM) for neuroendocrine cancer patients with progressive, differentiated, metastatic neuroendocrine tumors (NETs). Patients with carcinoid,…

9 Conferences for the Carcinoid and Neuroendocrine Tumor Community

If you are a carcinoid or NET cancer survivor, caregiver, family member or medical professional you can learn about what’s happening now and what’s new in carcinoid/NETs treatments, clinical trials, research, and more from specialists…

Carcinoid Cancer Foundation’s May 2011 Symposium Now Online

The Carcinoid Cancer Foundation is pleased to share with you videos from its carcinoid/NET symposium, “Neuroendocrine Tumor Management:  The Era of Personalized Medicine,” held on May 1, 2011 at Mt. Sinai Medical Center in New York City.

Following …

Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community

The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100  abstracts on carcinoid…